Trade

with

ACADIA Pharmaceuticals Inc
(NASDAQ: ACAD)
AdChoices
26.92
+0.67
+2.55%
After Hours :
26.92
0.00
0.00%

Open

26.24

Previous Close

26.25

Volume (Avg)

1.01M (1.19M)

Day's Range

26.06-26.95

52Wk Range

15.64-32.00

Market Cap.

2.68B

Dividend Rate ( Yield )

-

Beta

2.88

Shares Outstanding

99.44M

P/E Ratio (EPS)

-

AdChoices
Financials
  • Income Statement
  • Balance Sheet
  • Cash Flow
Operating Income
-38.30M
Operating Margin
-3,344.72
Total Equity
-
Retained Earnings
-
Free Cashflow
-
Price/Cashflow
-
Ownership

Institutional Ownership

-

Top 10 Institutions

83.58%

Mutual Fund Ownership

42.24%

Float

63.03%

5% / Insider Ownership

0.33%

Corporate insiders or major stockholders reporting trading activity in the stock.

Top Mutual Fund Owners

Top Institutional Owners

Mutual Fund Name

Institution Name

  • Mutual Fund Name

  • Shares Held

  • % Change

  • % Outstanding

  • Fidelity® Select Biotechnology Portfolio

  •  

    4,456,364

  • 0.18

  • 4.48

  • Fidelity® Growth Company Fund

  •  

    2,795,397

  • 1.42

  • 2.81

  • T. Rowe Price Health Sciences Fund

  •  

    2,141,800

  • 179.46

  • 2.16

  • T. Rowe Price New Horizons Fund

  •  

    1,786,800

  • 149.38

  • 1.80

  • Franklin Biotechnology Discovery

  •  

    1,443,000

  • 82.66

  • 1.46

  • Vanguard Small Cap Index

  •  

    1,381,813

  • 0.11

  • 1.39

  • Vanguard Total Stock Mkt Idx

  •  

    1,298,480

  • 0.18

  • 1.31

  • iShares Nasdaq Biotechnology

  •  

    1,285,582

  • -0.47

  • 1.37

  • Fidelity® Puritan® Fund

  •  

    1,207,500

  • 0.00

  • 1.21

  • iShares Russell 2000 (AU)

  •  

    1,173,113

  • -1.46

  • 1.25

  • Institution Name

  • Shares Held

  • % Change

  • % Outstanding

  • Baker Bros Advisors LLC

  •  

    20,481,442

  • 0.00%

  • 20.63

  • Fidelity Management and Research Company

  •  

    14,843,448

  • +1.49%

  • 14.95

  • T. Rowe Price Associates, Inc.

  •  

    5,962,463

  • +114.21%

  • 6.00

  • Vanguard Group, Inc.

  •  

    4,829,652

  • +0.83%

  • 4.86

  • Viking Global Investors LP

  •  

    4,757,878

  • +32.22%

  • 4.79

  • Jennison Associates LLC

  •  

    3,053,525

  • +0.13%

  • 3.08

  • BlackRock Fund Advisors

  •  

    2,935,943

  • -4.29%

  • 2.96

  • Westfield Capital Management Company, LP

  •  

    2,308,261

  • -1.67%

  • 2.32

  • Franklin Advisers, Inc.

  •  

    2,124,600

  • +70.68%

  • 2.14

Company Profile

Sector

Healthcare

Industry

Biotechnology

Type

Distressed

Style

Small Growth

ACADIA Pharmaceuticals Inc was incorporated in Vermont in 1993 as Receptor Technologies, Inc. The Company reincorporated in Delaware in 1997. It is a biopharmaceutical Company engaged in the development and commercialization of small...more molecule drugs for the treatment of central nervous system disorders. It has four product candidates in clinical development led by pimavanserin, which is in Phase III development as a potential first-in-class treatment for Parkinsons disease psychosis. Pimavanserin is a new chemical entity that the Company discovered and has advanced to Phase III development as a potential first-in-class treatment for Parkinsons disease psychosis. Parkinsons disease psychosis is a debilitating disorder that develops in up to 60 percent of patients with Parkinsons disease. The Company h...moreas completed a Phase II trial with pimavanserin as a co-therapy in schizophrenia and has established plans for a future Phase II feasibility study to explore the use of pimavanserin as a treatment for Alzheimers disease psychosis. In collaboration with Allergan, it has discovered and is developing small molecule product candidates for the treatment of chronic pain. Chronic pain is a common form of persistent pain that may be related to a number of medical conditions and is often resistant to treatment. Allergan has conducted several Phase II trials in this program and has reported preliminary results, including positive proof-of-concept in a human visceral pain trial and efficacy signals in two chronic pain trials in the areas of fibromyalgia and irritable bowel syndrome. The Company has discovered and, in collaboration with Allergan, is developing a small molecule product candidate for the treatment of glaucoma. Glaucoma is a chronic eye disease and is the second leading cause of blindness in the world. This program has reached Phase I development. ACADIA and R-SAT are company's registered trademarks. The Company faces competition from pharmaceutical and biotechnology companies, as well as numerous academic and research institutions and governmental agencies, both in the United States and abroad. It is subject to federal, state and local laws and regulations governing the use, storage, handling, and disposal of these materials and specified waste products.lessless

Key People

Dr. Uli Hacksell,PhD

CEO/Director/President

Dr. Leslie L. Iversen,PhD

Chairman of the Board/Director

Mr. Stephen R. Davis

CFO/Chief Accounting Officer/Executive VP/Other Executive Officer

Dr. Roger M. Mills,M.D.

Chief Medical Officer/Executive VP, Divisional

Terrence O. Moore

Executive VP/Other Executive Officer

Incorporated

1993

Employees

-

Send Feedback

We appreciate your input!

  • I'm having trouble signing into my Microsoft account

  • I’m having problems with the services stripe (Mail, Facebook, etc.)

  • There is an issue with my weather information

  • I see an error in the content

  • Other

Please give an overall site rating: